The higher plasma PCSK9 levels in statin users in NGT, PreDM and T2D groups compared with the non-statin users are in line with our earlier results, demonstrating that prediabetic subjects under statin therapy had higher plasma PCSK9 levels compared with untreated subjects [24]. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.